Waystar Weighs Sale Amid Stock Decline, Sources Reveal

Waystar, a notable player in healthcare software, is reportedly exploring strategic options, including a potential sale. This move comes amid a significant drop in its market value, which now stands at approximately $4.8 billion. Sources familiar with the situation indicated that the company has engaged investment bank Evercore to assist in the process, although the discussions are still in early stages.

Market Pressures and Strategic Positioning

The Lehi, Utah, and Louisville, Kentucky-based firm, which provides software solutions for payment management in hospitals and clinics, is evaluating its future as its share price has plummeted by 24% this year. This decline reflects broader trends in the software sector, where investor confidence has been shaken. Despite its initial positioning as a tech-centric company, Waystar has faced challenges from emerging technologies such as artificial intelligence, which have raised concerns about the future of traditional software models.

Waystar was established from the 2017 merger of Zirmed and Navicure, both leaders in healthcare revenue management. The company went public in 2024, backed by significant investors including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT holds the largest stake at 13%, followed by CPPIB at 10% and BlackRock Institutional Trust Company at 8%, according to LSEG data.

Potential Sale and Investor Interest

While Waystar has not confirmed any definitive plans, the potential sale could return the company to private ownership just two years after its public debut. The current exploration could also serve to test market interest in healthcare software firms, which have seen fluctuating valuations due to technological advancements and market conditions.

Despite the downturn in its share price, Waystar's strategy to emphasize its technological capabilities rather than traditional healthcare services aimed to attract higher valuations. Initially, this approach garnered positive attention, with shares rising from $20 to a peak of $45 in 2025. However, the subsequent decline has prompted reconsideration of its market position.

Stakeholders' Stance

Neither Waystar nor its major stakeholders, including EQT, CPPIB, and BlackRock, have publicly commented on the potential sale. Evercore, the investment bank advising on the process, also did not respond to requests for comments. The outcome of these deliberations remains uncertain, with possibilities ranging from a full sale to other strategic alternatives.

The decision by Waystar to evaluate its options highlights the ongoing volatility in the software industry, particularly for companies bridging the gap between healthcare and technology. As the situation develops, stakeholders and investors alike will be keenly observing for any shifts that could impact the company's direction and valuation.